Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
22181
Gene expression profiles & Gene set Enrichment analysis.
Published 2025“…Genes were filtered using a threshold of p-value ≤ 0.05 and (|Fold Change|) ≥ 2 Both rows (genes) and columns (samples) were subjected to hierarchical clustering. …”
-
22182
Expression levels of p115RhoGEF affect cell migration.
Published 2014“…Individual cell positions in sequential images were determined using the cell tracking tool in Slidebook software and x-y co-ordinates with starting points adjusted to (0,0) were plotted. Migration of 5 cells was measured in each experiment and data was pooled from three individual experiments. p115-OE MDA-MB-231 cells displayed decreased migration as compared to control cells that expressed GFP alone. …”
-
22183
-
22184
-
22185
-
22186
-
22187
-
22188
-
22189
-
22190
-
22191
-
22192
Astilbin exerts anti-hypersensitivity by regulating metabolic demand and neuronal activity in rodent model of neuropathic pain
Published 2024“…</p> <p>In experiments conducted on neuropathic rats, both systemic and intrathecal administration of astilbin, an essential constituent, exhibited a noteworthy and dose-dependently decrease in chronic and acute pain behaviours. …”
-
22193
Tubulin-Destabilizing Agent BPR0L075 Induces Vascular-Disruption in Human Breast Cancer Mammary Fat Pad Xenografts
Published 2012“…The current study evaluated the vascular-disrupting activity of BPR0L075 in human breast cancer mammary fat pad xenografts using dynamic bioluminescence imaging. A single dose of BPR0L075 (50 mg/kg, intraperitoneally (i.p.)) induced rapid, temporary tumor vascular shutdown (at 2, 4, and 6 hours); evidenced by rapid and reproducible decrease of light emission from luciferase-expressing orthotopic MCF7 and MDA-MB-231 breast tumors after administration of luciferin substrate. …”
-
22194
-
22195
-
22196
-
22197
-
22198
-
22199
-
22200